• 1. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 2. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 3. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 4. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 5. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565

Research Briefing on N,5,6-Trimethyl-1,3-benzothiazol-2-amine (CAS: 62194-25-6): Recent Advances and Applications

N,5,6-Trimethyl-1,3-benzothiazol-2-amine (CAS: 62194-25-6) is a benzothiazole derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug development. This compound, characterized by its unique structural features, has been the subject of numerous studies exploring its biological activities, synthetic pathways, and therapeutic potential. This briefing provides an overview of the latest research findings related to this compound, focusing on its chemical properties, pharmacological effects, and emerging applications in the field of chemical biology and medicine.

Recent studies have highlighted the role of N,5,6-trimethyl-1,3-benzothiazol-2-amine as a key intermediate in the synthesis of bioactive molecules. Its benzothiazole core is known to exhibit a wide range of biological activities, including antimicrobial, anti-inflammatory, and anticancer properties. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit potent inhibitory effects against specific kinase targets involved in cancer cell proliferation. The study utilized molecular docking and in vitro assays to validate the compound's binding affinity and efficacy, suggesting its potential as a lead compound for further drug development.

In addition to its anticancer potential, N,5,6-trimethyl-1,3-benzothiazol-2-amine has also been investigated for its antimicrobial properties. A recent publication in Bioorganic & Medicinal Chemistry Letters reported that this compound and its analogs exhibit significant activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The researchers attributed this activity to the compound's ability to disrupt bacterial cell wall synthesis, making it a promising candidate for the development of novel antibiotics. Further structure-activity relationship (SAR) studies are underway to optimize its antimicrobial potency and reduce potential toxicity.

The synthetic pathways for N,5,6-trimethyl-1,3-benzothiazol-2-amine have also been a focus of recent research. A 2024 study in Organic & Biomolecular Chemistry described an efficient, one-pot synthesis method for this compound, utilizing readily available starting materials and mild reaction conditions. This advancement not only improves the scalability of production but also reduces the environmental impact associated with traditional synthetic routes. The study emphasized the importance of green chemistry principles in the development of pharmaceutical intermediates, aligning with the growing demand for sustainable drug manufacturing processes.

Despite these promising findings, challenges remain in the clinical translation of N,5,6-trimethyl-1,3-benzothiazol-2-amine-based therapeutics. Issues such as bioavailability, metabolic stability, and off-target effects need to be addressed through further preclinical studies. Recent efforts have focused on prodrug strategies and formulation technologies to enhance the compound's pharmacokinetic profile. For instance, a 2023 patent application disclosed a novel liposomal formulation of this compound, designed to improve its solubility and targeted delivery to tumor tissues.

In conclusion, N,5,6-trimethyl-1,3-benzothiazol-2-amine (CAS: 62194-25-6) represents a versatile scaffold with broad potential in drug discovery and development. Its diverse biological activities, coupled with recent advances in synthetic methodologies, position it as a valuable tool for researchers in chemical biology and medicinal chemistry. Future studies should focus on elucidating its mechanism of action, optimizing its pharmacological properties, and exploring its therapeutic applications in various disease models. The continued investigation of this compound and its derivatives is expected to yield significant contributions to the field of biomedicine in the coming years.

• 29927-08-0(5,6-dimethyl-1,3-benzothiazol-2-amine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)